Review anchor
Myosin light chain kinase 2, skeletal/cardiac muscle
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
Evidence Snapshot
Myosin light chain kinase 2, skeletal/cardiac muscle
CHEMBL2777
SINGLE PROTEIN
Homo sapiens
Identity Layer
Cross-source identity
Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats Myosin light chain kinase 2, skeletal/cardiac muscle as ChEMBL target CHEMBL2777, mapped to UniProt Q9H1R3. Disease framing currently uses the Open Targets-ready proxy contract.
ChEMBL target ID
CHEMBL2777
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine
As of 2026-09-13
www.ebi.ac.uk
UniProt accession
Q9H1R3
Myosin light chain kinase 2, skeletal/cardiac muscle
UniProt accession via ChEMBL component mapping
As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy
As of 2026-09-13
www.ebi.ac.uk
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Review-ready Target Rationale
Why Myosin light chain kinase 2, skeletal/cardiac muscle matters
Myosin light chain kinase 2, skeletal/cardiac muscle is reviewed as Myosin light chain kinase 2, skeletal/cardiac muscle (UniProt Q9H1R3); the current evidence base includes 9 approved drugs, 401 compounds, and 192 assays, with lead potency reaching pChEMBL 7.9.
Protein context
Myosin light chain kinase 2, skeletal/cardiac muscle
Myosin light chain kinase 2, skeletal/cardiac muscle Sequence length is 596 aa.
Review this target as Myosin light chain kinase 2, skeletal/cardiac muscle, mapped to UniProt Q9H1R3. Sequence length is 596 aa.
Protein source · UniProt accession via ChEMBL component mapping
UniProt Q9H1R3
Protein
Disease context
Disease signal
Disease relevance is not yet populated for this evidence card.
This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
ChEMBL target recordActivity base
Portfolio and assay base
ChEMBL currently tracks 9 approved drugs, 401 compounds, and 192 assays for this target. The dominant activity type is KD. CHEMBL388978 is the current potency anchor at pChEMBL 7.9.
Use CHEMBL388978 as the tractability anchor when discussing potency (pChEMBL 7.9).
Activity source · ChEMBL 36 via Core Engine
9 approved
pChEMBL 7.9
Source Guidance
Start with the right source
Pick the first block or linked source that matches the review question in front of you.
Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution
Start with the review rationale when you need to explain why Myosin light chain kinase 2, skeletal/cardiac muscle matters before drilling into raw source blocks.
Jump to Review RationaleNeed stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping
Go back to the target snapshot when you need the naming and mapping contract behind UniProt Q9H1R3, not just the summarized rationale.
Open Protein ContextNeed disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy
Use the target snapshot disease block when you need the disease program and supporting signals, not only the card summary.
Open Disease ContextSnapshot State
No project snapshot selected. Export uses the live evidence card state.
401
Total Compounds
192
Total Assays
9
Approved Drugs
IC50: 27.0, KD: 141.0
Activity Types
pChEMBL Activity Distribution
Top 5 Inhibitors (by pChEMBL)
| Structure | Compound | pChEMBL | Type | Phase |
|---|---|---|---|---|
|
|
No preferred name
CHEMBL388978
|
7.9 | IC50 | — |
|
|
No preferred name
CHEMBL572878
|
7.4 | Kd | Clinical |
|
|
No preferred name
CHEMBL535
|
7.3 | Kd | Approved |
|
|
No preferred name
CHEMBL1908397
|
7.3 | Kd | — |
|
|
No preferred name
CHEMBL603469
|
7.2 | Kd | Clinical |
Source Header